Sign in
8-K

Current Report

Larimar Therapeutics, Inc. Filed Acc 0001193125-19-244019

Exit or restructuring costs · Executive or director change

  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers

From the SEC's structured data for this filing

Loading d798377d8k.htm…